EUVIMEDObjevte EUVIMED
Crossref

Plasma calcitonin gene–related peptide and nerve growth factor as headache and pain biomarkers in recently deployed soldiers with and without a recent concussion

Ann I Scher, James S McGinley, Lyndsey R VanDam, Amanda M Campbell, Xiyun Chai, Billy Collins, Scott A Klimp, Alan G Finkel iD, Karen Schwab, Richard B Lipton, Kirk W Johnson

Headache: The Journal of Head and Face Pain · 2023-10 · 63 (9) · 1240-1250

DOI: 10.1111/head.14635 ↗

At a glance

Journal article in Headache: The Journal of Head and Face Pain, published online on 2023-10-05. Written by Ann I Scher and 10 co-authors. Institution: Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA. Major MEDLINE topics: Military Personnel, Post-Traumatic Headache, Brain Concussion, Brain Injuries, Traumatic. Cited 13 times so far (Crossref); 42 references. Funded by: Center for Neuroscience and Regenerative Medicine, Congressionally Directed Medical Research Programs, Eli Lilly and Company.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Objective

The objective of this study was to characterize the utility of calcitonin gene–related peptide (CGRP) and nerve growth factor (NGF) as potential biomarkers for headache and pain disorders in the post–military deployment setting.

Background

The need to improve recognition, assessment, and prognoses of individuals with posttraumatic headache or other pain has increased interest in the potential of CGRP and NGF as biomarkers.

Methods

The Warrior Strong Study (NCT01847040) is an observational longitudinal study of United States–based soldiers who had recently returned from deployment to Afghanistan or Iraq from 2009 to 2014. The present nested cross‐sectional analysis uses baseline data collected from soldiers returning to Fort Bragg, North Carolina.

Results

In total, 264 soldiers (mean (standard deviation [SD] age 28.1 [6.4] years, 230/264 [87.1%] men, 171/263 [65.0%] White) were analyzed. Mean (SD) plasma levels of CGRP were 1.3 (1.1) pg/mL and mean levels of NGF were 1.4 (0.4) pg/mL. Age was negatively correlated with NGF (−0.01 pg/mL per year, p = 0.007) but was not associated with CGRP. Men had higher mean (SD) CGRP plasma levels than women (1.4 95% confidence interval [CI; 1.2] vs. 0.9 95% CI [0.5] pg/mL, p < 0.002, Kruskal–Wallis test). CGRP levels were lower in participants who had a headache at the time of the blood draw (1.0 [0.6] pg/mL vs. 1.4 [1.2] pg/mL, p = 0.024). NGF was lower in participants with continuous pain (all types; 1.2 [0.4] vs. 1.4 [0.4] pg/mL, p = 0.027) and was lower in participants with traumatic brain injury (TBI) + posttraumatic headache (PTH) versus TBI without PTH (1.3 [0.3] vs. 1.4 [0.4] pg/mL, p = 0.021). Otherwise, CGRP and NGF were not associated with migraine‐like headache, TBI status, or headache burden as measured by the number of medical encounters in crude or adjusted models.

Conclusion

In this exploratory study, plasma levels of NGF and CGRP showed promise as biomarkers for headache and other types of pain. These findings need to be replicated in other cohorts.

Subjects

MeSH terms (MEDLINE)

Military PersonnelPost-Traumatic HeadacheBrain ConcussionBrain Injuries, TraumaticMaleHumansFemaleUnited StatesAdultCalcitonin Gene-Related PeptideLongitudinal StudiesCross-Sectional StudiesNerve Growth FactorHeadachePainBiomarkers

Author keywords

biomarkercalcitonin gene-related peptideconcussionmild traumatic brain injurynerve growth factorposttraumatic headache

Substances

Calcitonin Gene-Related PeptideNerve Growth FactorBiomarkers

Authors and institutions

  • Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Vector Psychometric Group, Chapel Hill, North Carolina, USA.
  • Pain Research, Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Precision Medicine Neuroscience, AbbVie, Chicago, Illinois, USA.
  • US Public Health Service Commissioned Corps, Fayetteville, North Carolina, USA.
  • Womack Army Medical Center, Fort Bragg, North Carolina, USA.

ORCID profiles: Alan G Finkel

Funding

  • Center for Neuroscience and Regenerative Medicine
  • Congressionally Directed Medical Research Programs
  • Eli Lilly and Company

Cite

APA

Scher, A. I., McGinley, J. S., VanDam, L. R., Campbell, A. M., Chai, X., Collins, B., Klimp, S. A., Finkel, A. G., Schwab, K., Lipton, R. B., & Johnson, K. W. (2023). Plasma calcitonin gene–related peptide and nerve growth factor as headache and pain biomarkers in recently deployed soldiers with and without a recent concussion. Headache: The Journal of Head and Face Pain, 63(9), 1240-1250. https://doi.org/10.1111/head.14635

Vancouver

Scher AI, McGinley JS, VanDam LR, Campbell AM, Chai X, Collins B, et al. Plasma calcitonin gene–related peptide and nerve growth factor as headache and pain biomarkers in recently deployed soldiers with and without a recent concussion. Headache: The Journal of Head and Face Pain. 2023;63(9):1240-1250. doi:10.1111/head.14635

BibTeX
@article{Scher2023,
  author = {Scher, Ann I and McGinley, James S and VanDam, Lyndsey R and Campbell, Amanda M and Chai, Xiyun and Collins, Billy and Klimp, Scott A and Finkel, Alan G and Schwab, Karen and Lipton, Richard B and Johnson, Kirk W},
  title = {Plasma calcitonin gene–related peptide and nerve growth factor as headache and pain biomarkers in recently deployed soldiers with and without a recent concussion},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2023},
  volume = {63},
  number = {9},
  pages = {1240--1250},
  doi = {10.1111/head.14635}
}
Start for free →